Jun 5, 2026
•
6 min read
CNBC: "Buying stuff like it's going out of fashion." The Supreme Court sided with Hikma on Vascepa patents. Lilly's Medicare deal restores Foundayo and Zepbound coverage. And Gilead cut 87% of Arcellx's workforce post-acquisition.
Jun 4, 2026
5 min read
Ascidian brings RNA exon editing for kidney disease in a $1.9B collaboration. BMS taps Anthropic for AI drug development. Moderna links up on Ebola vaccines. Lilly and Boehringer pulled $1B+ each from Germany. Jefferies conference opens today.
Jun 3, 2026
Pfizer locked in $10.5B with Innovent for 12 cancer programs. Lilly added $3B+ with Haisco for five programs. That's Lilly's 11th deal this year. Combined with BMS/Hengrui, three mega China licensing deals landed in a single month.
Jun 2, 2026
Bladder cancer got a 55.8% complete response rate with an ADC combo. Lilly's Kelonia justified its $3.2B price tag. Apogee locked in $1.3B from Blackstone. Hengrui presented 90+ studies. And the obesity conference is next.
Revolution doubled survival in pancreatic cancer and published in the NEJM. A Chinese bispecific beat PD-1 on overall survival in lung cancer. J&J shifted a 125-year prostate cancer paradigm. The FDA granted expanded access to daraxonrasib. Here's all of it.
40,000 attendees. 7,000 abstracts. Revolution's plenary is tomorrow morning. Lantheus got a $7B take-private offer from Curium. AbbVie landed a rare blood cancer approval. BridgeBio got Priority Review for a muscular dystrophy drug.
ASCO abstracts are out. sac-TMT plus Keytruda versus Keytruda alone in first-line lung cancer: 65% lower risk of progression or death. ASCO opens tomorrow. Revolution's plenary is Saturday. The abstracts signal the most data-rich oncology meeting in years.
Curevo (shingles), LimmaTech (bacterial AMR), and Vaccine Company (Epstein-Barr virus). That's deals 8, 9, and 10 this year. Total 2026 M&A now exceeds $25B. ASCO opens tomorrow. Revolution's plenary is Saturday.
Baxfendy is the first new hypertension mechanism in two decades. Mineralys' rival has a December PDUFA. ASCO opens Thursday with Revolution's plenary on Saturday. Plus the device tariff report is overdue.
Revolution Medicines presents full Phase 3 pancreatic cancer data in a plenary session on Saturday. A new ADC was approved for triple-negative breast cancer. Gilead got the first-ever HDV treatment approved. And the EU locked in its supply chain law.
Retatrutide delivered 28.3% weight loss (70.3 lbs) at 80 weeks. Extension patients lost 30.3% at 104 weeks. Truist projects $12B to $19B in peak sales. Lilly also made its seventh acquisition of the year. ASCO is 9 days out.
Five CDER heads in one year. Fewer than half of senior FDA leaders from six months ago remain. Capital Alpha called it "the most damaging period in FDA history." Relay outpaced Novartis in rare disease. AbbVie locked Rinvoq generics out until 2037.
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
